Payagala S, Pozniak A (Feb. 2024) The global burden of HIV. Clin Dermatol 42(2):119–127.Feb.https://doi.org/10.1016/j.clindermatol.2024.02.001

Article  PubMed  Google Scholar 

Lu Y et al (1928) Global and regional disease burden of HIV/AIDS from 1990 to 2021 and projections to 2030., BMC Public Health, 25, 1, May 2025. https://doi.org/10.1186/s12889-025-23121-4

Magomere E et al (2025) The Confluence of HIV-1 and HIV-2: Implications for Disease Progression and Insights for Therapy., Int. J. Microbiol, 3145677, Jul. 2025. https://doi.org/10.1155/ijm/3145677

Fanjul F et al (Oct. 2025) HIV Therapy: The Latest Developments in Antiviral Drugs-A Scoping Review. Biomedicines 13(11). https://doi.org/10.3390/biomedicines13112629

Gandhi RT et al (2025) Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel., JAMA, 333(7):609–628, Feb. https://doi.org/10.1001/jama.2024.24543

Article  PubMed  CAS  Google Scholar 

Kolakowska A, Maresca AF, Collins IJ, Cailhol J (2019) Update on adverse effects of HIV integrase inhibitors. Curr Treat Options Infect Dis 11(4):372–387. https://doi.org/10.1007/s40506-019-00203-7

Article  PubMed  PubMed Central  Google Scholar 

Gibas KM, Dec (2022) Two-drug regimens for HIV treatment. Lancet HIV 9(12):e868–e883. https://doi.org/10.1016/S2352-3018(22)00249-1

Article  PubMed  PubMed Central  CAS  Google Scholar 

McCluskey SM, Gandhi M (2025) Predictors of treatment-emergent resistance to dolutegravir. Lancet HIV 12(9):e660–e663. Sep. https://doi.org/10.1016/S2352-3018(25)00127-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Organization WH (2024) HIV drug resistance brief report 2024. World Health Organization, p 46

Williams V, Cory TJ, Jan (2025) Doravirine/islatravir for the treatment of HIV. Expert Opin Pharmacother 26(1):9–15. https://doi.org/10.1080/14656566.2024.2440000

Article  PubMed  CAS  Google Scholar 

Deeks ED, Oct (2018) Doravirine: first global approval. Drugs 78(15):1643–1650. https://doi.org/10.1007/s40265-018-0993-4

Article  PubMed  Google Scholar 

Schürmann D, Lancet HIV et al (2020) 7, 3, pp. e164–e172, Mar. https://doi.org/10.1016/S2352-3018(19)30372-8

Colson AE et al (2026) Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet 407(10528):611–621. https://doi.org/10.1016/S0140-6736(25)01948-8

Article  PubMed  CAS  Google Scholar 

Mills AM (Jun et al (eds) (2024) Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV 11(6):e357–e368. https://doi.org/10.1016/S2352-3018(24)00030-4

Molina J-M et al (2024) Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV 11(6):e369–e379. https://doi.org/10.1016/S2352-3018(24)00031-6

Article  PubMed  CAS  Google Scholar 

Orkin C et al (2026) Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet 407(10528):599–610. https://doi.org/10.1016/S0140-6736(25)01945-2

Article  PubMed  CAS  Google Scholar 

Rockstroh JK et al (2025) Sep., Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clin Infect Dis 81(2):322–332. https://doi.org/10.1093/cid/ciaf077

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rockstroh JK et al (2026) Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial., Lancet HIV, Feb. https://doi.org/10.1016/S2352-3018(26)00033-0

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https://doi.org/10.1186/s13643-016-0384-4

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Aug (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

Article  PubMed  Google Scholar 

McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55–61. https://doi.org/10.1002/jrsm.1411

Article  PubMed  Google Scholar 

Balduzzi S, Rücker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153–160. https://doi.org/10.1136/ebmental-2019-300117

Article  PubMed  PubMed Central  Google Scholar 

Guyatt GH, (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926. Apr https://doi.org/10.1136/bmj.39489.470347.AD

Article  PubMed  PubMed Central  Google Scholar 

Sjaarda A, Bernstein A, Sparks A, Saber S, Siegel M (2022) Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Infection 50(2):407–412. https://doi.org/10.1007/s15010-021-01687-6

Article  PubMed  CAS  Google Scholar 

Palella FJ et al (2023) Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide. J Acquir Immune Defic Syndr 92(1):67–75. https://doi.org/10.1097/QAI.0000000000003101

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zang X, (2024) Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrob Agents Chemother 68(9):e0045824. Sep https://doi.org/10.1128/aac.00458-24

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maas BM et al (2026) P-344. Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4 + T-cell Counts in People Living with HIV, Open Forum Infect. Dis., 13, Supplement_1, Jan. https://doi.org/10.1093/ofid/ofaf695.562

Eckard AR, McComsey GA (2020) Weight gain and integrase inhibitors. Curr Opin Infect Dis 33(1):10–19 Feb. 10.1097/QCO.0000000000000616 https://doi.org/10.1097/QCO.0000000000000616

Article  PubMed  PubMed Central  Google Scholar 

Savinelli S, Newman E, Mallon PWG (2024) Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism. Curr HIV/AIDS Rep 21(6):293–308. https://doi.org/10.1007/s11904-024-00708-x

Article  PubMed  PubMed Central  Google Scholar 

Talwani R, Temesgen Z, Feb (2020) Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs Today 56(2):113–124. https://doi.org/10.1358/dot.2020.56.2.3109966

Article  CAS  Google Scholar 

Zalenski N, Jun (2025) Kinetic Investigation of Resistance to Islatravir Conferred by Mutations in HIV-1 Reverse Transcriptase. J Mol Biol 437(12):169100. https://doi.org/10.1016/j.jmb.2025.169100

Article  PubMed  CAS  Google Scholar 

Byun H, Papathanasopoulos MA, Steegen K, Basson AE (Dec. 2024) Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses 16(12). https://doi.org/10.3390/v16121888

Fraysse J, Feb (2025) Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis. Infect Dis Ther 14(2):357–383. https://doi.org/10.1007/s40121-024-01103-0

Article  PubMed  PubMed Central  Google Scholar 

Doblado-Maldonado A et al (2025) Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review. Med (Baltim) 104(33):e43558. https://doi.org/10.1097/MD.0000000000043558

Article  Google Scholar 

Llibre JM et al (Sep. 2025) Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens. Clin Infect Dis. https://doi.org/10.1093/cid/ciaf471